Hannah Linden

Hannah Linden, MD, is a Professor at the University of Washington School of Medicine's Medical Oncology Division and an integral faculty member at Fred Hutchinson Cancer Center's Clinical Research Division. She serves as the Associate Program Director for the Medical Oncology and Hematology Fellowship Program at Fred Hutch and UW Medicine, treating breast cancer patients at Fred Hutchinson Cancer Center and Harborview Medical Center. Her clinical expertise lies in hormone therapy targeting estrogen receptors.

• Education:
  • MD, University of Massachusetts (1989)
  • BA, cum laude, Yale University (1985)
  • Residency: University of Arizona Medical Center (1989-1992)
  • Fellowship: Pharmacology, University of Arizona Medical Center (1992-1993)
  • Fellowship: Hematology, University of Washington School of Medicine (1993-1994)
  • Senior Research Fellow: Hematology, University of Washington (1994-2002)

Dr. Linden's research focuses on understanding resistance to endocrine therapy in breast cancer, developing molecular imaging techniques (e.g., PET scans for therapy monitoring), and improving access to clinical trials for underserved populations. She leads pivotal studies in advanced breast cancer treatments and pharmacodynamic imaging.

Scientific Awards & Leadership: She has received the Athena Distinguished Professorship of Breast Cancer Research. Her clinical trials include the OVELIA Study (Phase III), Alisertib trials (Phase II), and functional imaging studies for endocrine therapy response.